Acne vulgaris is a multifactorial skin disease, characterized by proliferation of
bacteria, hyperkeratinization, inflammation, and excess sebum production, mainly prevalent
in adolescents and young adults. Current over-the-counter treatment options include
topical therapies such as benzoyl peroxide (BPO) and salicylic acid, but patient adherence
to topical treatments can often be challenging. Various types of blue and red light-emitting
diodes (LEDs) have been used independently and in combination as an alternative, chemical-free
option for the treatment of acne. Recent research has further elucidated the antibacterial
efficacy of blue light (up to 440 nm) through its interaction with the porphyrin produced
by Propionbacterium acnes, and research has also demonstrated the significant antiinflammatory activity of
red light via modulation of cytokine release and its effect on hyperkeratinization.
A 12-week, multicenter, evaluator-blinded clinical study was conducted to evaluate
a new low-level blue and red light therapy technology in men and women (12-40 years
of age) with mild to moderate acne. Subjects were randomized at baseline to receive
either a once-per-day 10 minute treatment with the combination blue and red light
technology, or twice-per-day treatment with topical 2.5% BPO. The light therapy technology
provided simultaneous low-level blue and red exposure to the face, in 1-step, with
all product treatments able to be performed at home. The primary efficacy variable
was the percent change from baseline to week 12 in total lesion counts, with Investigator
Global Acne (IGA) assessment, self-assessment questionnaires, and skin tolerance also
evaluated throughout the course of the study. The new low-level blue and red light
therapy technology was found to be well-tolerated and significantly reduced total
acne lesion counts over the 12 week study compared with baseline (P < .05). Subjects also reported significant improvements (P < .05) in their acne and overall skin appearance, which is critical for continued
compliance to a daily treatment regimen. Improvement in the BPO group was also observed
throughout the course of the clinical study. This clinical study demonstrated the
efficacy and tolerance of a new low-level blue and red light therapy technology. This
1-step at-home light therapy now provides an effective, easy-to-use, chemical and
UV-free treatment option ideally suited for mild-to-moderate acne patients.
To read this article in full you will need to make a payment
AAD Member Login
AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
Already an online subscriber? Sign in
Dara Miller, Johnson & Johnson Consumer Inc.; Dana Friscia, Johnson & Johnson Consumer Inc.; Lisa Fitzgerald, Johnson & Johnson Consumer Inc.; Mei-Miau Wu, Johnson & Johnson Consumer Inc.
Commercial support: Study sponsored by Johnson & Johnson Consumer Inc.
© 2017 Published by Elsevier Inc.